Barely Significant
← all excerpts

Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia.

Blood Cancer J · 2025 · PMC12284254 · PMID 40695828

Europe PMCDOI
1
hedged sentence
0.0300
closest p · 0.6× alpha
0.0300
boldest claim

The sentences

showed a trendp = 0.03actually significant
In addition, the HSCT subgroup showed a trend toward improved OS compared with the non-HSCT subgroup, with 2-year OS rates of 92.3% and 53.9%, respectively ( p = 0.03) (Fig. 1E, F ).

also in 23,610 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.